Blackstone and TPG acquires Hologic

Blackstone and TPG have finalized the acquisition of Hologic, Inc., a leader in women's health, in a transaction worth up to $18.3 billion. This deal, marking a significant shift for Hologic, transitions the company from public to private ownership. The acquisition, completed through funds managed by Blackstone and TPG, includes minority investments by the Abu Dhabi Investment Authority and GIC. José E. Almeida has been appointed as the new CEO, replacing Stephen MacMillan.

The financial terms of the acquisition involve Hologic's shareholders receiving $76 per share in cash, along with a contingent value right (CVR) potentially worth an additional $3 per share. These CVRs are dependent on meeting specified revenue targets in the company's Breast Health division over the next two fiscal years. The acquisition, first announced in October 2025, gained shareholder approval in early February 2026.

Strategically, Blackstone and TPG aim to leverage their partnership to bolster Hologic's position as a global frontrunner in advancing women's health technologies. José Almeida, with his extensive experience at Baxter International and Covidien, is seen as pivotal to steering Hologic towards further innovation and market expansion. Almeida's leadership is expected to enhance Hologic's initiatives, focusing on operational improvements and expanding its medical technology portfolio.

In taking Hologic private, Blackstone and TPG intend to drive the next phase of growth without the pressure of quarterly earnings reports, allowing for longer-term strategic planning. This acquisition places emphasis on healthcare innovation, particularly in women's health — a growing focus within the sector as companies seek to address under-served market needs.

Looking forward, the primary challenges will likely center around hitting the revenue benchmarks necessary for the contingent payouts to shareholders. Market analysts will watch closely how Almeida and his team mobilize to achieve these targets, considering the increased capital resources now at their disposal. Hologic's delisting from Nasdaq completes the company's transition to private status, setting the stage for its strategic realignment under new ownership.